Hep C - Third Wave settles with Belgian firm

Third Wave settles with Belgian firm
bizjournals.com via Yahoo! Finance - Feb 09 1:08 PM
Third Wave Technologies Inc. will be allowed to sell hepatitis C analysis products in the United States under a patent litigation settlement with a Belgian firm.Save to My Web

Peregrine Announces Completion of Planned Patient Enrollment and Dosing in Initial Tarvacin(TM) Anti-Viral Hepatitis C
[Press Release] PR Newswire via Yahoo! Finance - Feb 15 4:00 AM
Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for viral diseases and cancer, today announced that it has completed planned patient enrollment and dosing in its initial Phase l clinical trial for Tarvacin Anti-Viral in the treatment of chronic hepatitis C virus infection .Save to My Web

ViroPharma to Release 2005 Fourth Quarter and Full Year Financial Results on February 28, 2006
[Press Release] PR Newswire via Yahoo! Finance - Feb 16 9:41 AM
ViroPharma Incorporated's fourth quarter and year end financial results for 2005 and guidance for 2006 are expected to be released on Tuesday, February 28, 2006 before the open of the U.S. financial markets.Save to My Web

China: Hepatitis Treatment Fails to Keep Pace With Economy
RedNova - Feb 07 10:29 PM
According to a statement recently made by a senior health official in China, improvements in disease management and prevention have helped to transform infectious disease healthcare in China.Save to My Web

Vertex drug lowers hepatitis C virus to undetectable levels
PharmaBiz - Feb 08 3:37 AM
Vertex Pharmaceuticals Incorporated has successfully completed dosing with VX-950 in a phase II, 28-day clinical study in hepatitis C virus (HCV) infected patients. The clinical trial showed that its hepatitis C treatment lowered virus levels to undetectable levels.Save to My Web